Dexmedetomidine Attenuates Neonatal Hypoxic-Ischemic Encephalopathy by Inhibiting Microglia Activation Through...

Area of Science:

• Neuroscience
• Neonatal Research
• Pharmacology

Background:

• Neonatal hypoxic-ischemic encephalopathy (NHIE) is a major cause of infant mortality and disability.
• Dexmedetomidine (Dex) shows neuroprotective potential.
• Microglia activation and inflammation are key pathological features of NHIE.

Purpose of the Study:

• To investigate the protective mechanisms of Dex in NHIE.
• To identify molecular targets of Dex in NHIE.
• To elucidate the role of Rbm47 in Dex-mediated neuroprotection.

Main Methods:

• Hypoxia-ischemia (HI) model in neonatal rats and BV2 microglial cells.
• Administration of Dexmedetomidine (Dex).
• Assessment of brain injury, neurological deficits, inflammation, and microglia polarization.
• Analysis of Rbm47 expression and function via overexpression and knockdown.

Main Results:

• HI induced significant brain injury, neurological deficits, and inflammation in rats.
• Dex treatment attenuated HI-induced brain damage and reduced microglial M1 polarization.
• Rbm47 was downregulated in NHIE and upregulated by Dex; its overexpression mimicked Dex's protective effects.
• Rbm47 knockdown abolished Dex's anti-inflammatory and anti-M1 polarization effects in BV2 cells.

Conclusions:

• Dexmedetomidine exerts neuroprotection against NHIE through Rbm47.
• Rbm47 is a critical mediator of Dex's protective effects by modulating microglial activation and inflammation.
• Targeting Rbm47 may represent a therapeutic strategy for NHIE.